Trial Profile

A Randomized, Open Labelled Trial of Continuation of Adefovir Plus Lamivudine Versus Switching to Adefovir Plus Entecavir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Adefovir Plus Lamivudine.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
02 Dec 2010 The treatment duration changed from 52 weeks to 104 weeks according to ClinicalTrials.gov record.
02 Dec 2010 Planned End Date changed from 1 Dec 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com